Morená Leela, Al Jurdi Ayman, El Mouhayyar Christopher, Verhoeff Rucháma, Alzahrani Nora, N Kotton Camille, V Riella Leonardo
Division of Transplant Surgery, Center for Transplantation Sciences, Massachusetts General Hospital, Boston, MA.
Harvard Medical School, Boston, MA.
Transplant Direct. 2024 Aug 8;10(9):e1690. doi: 10.1097/TXD.0000000000001690. eCollection 2024 Sep.
In solid organ transplant recipients (SOTRs), studies investigating post-acute sequelae of SARS-CoV-2 infection (PASC) are limited, and risk factors for their development require further investigation.
In this cross-sectional study, we evaluated PASC symptoms among SOTRs followed at our institutions who had COVID-19 during the Omicron period from December 28, 2021, to November 4, 2022. Participants were surveyed using a newly published PASC score containing 13 symptoms experienced for ≥30 d. PASC was defined as a score of ≥12.
Of 299 SOTRs invited, 93 completed the survey and were analyzed. The mean age was 58 y and 43% were women. Forty-six individuals (49%) reported experiencing ≥1 PASC symptom for ≥30 d, of whom 13 (14%) met the PASC definition. Multivariable analysis showed that female sex (adjusted odds ratio [aOR] = 0.32; 95% confidence interval [CI], 0.12-0.83), years from transplantation (aOR = 0.90 per additional year; 95% CI, 0.81-0.99), and tixagevimab-cilgavimab preexposure prophylaxis (aOR = 0.33; 95% CI, 0.12-0.84) were associated with significantly lower odds of developing ≥1 PASC symptom.
PASC symptoms are common in SOTRs infected during the Omicron period. PASC symptoms are less frequent in those with a longer time since transplant and in those who received tixagevimab-cilgavimab. New SARS-CoV-2 prevention and treatment strategies should also evaluate PASC symptoms as outcomes.
在实体器官移植受者（SOTR）中，关于严重急性呼吸综合征冠状病毒2感染后急性后遗症（PASC）的研究有限，其发生的危险因素需要进一步研究。
在这项横断面研究中，我们评估了2021年12月28日至2022年11月4日奥密克戎时期在我们机构随访的感染新型冠状病毒肺炎的SOTR中的PASC症状。使用新发布的包含13种持续≥30天症状的PASC评分对参与者进行调查。PASC定义为评分≥12。
在299名受邀的SOTR中，93名完成了调查并进行了分析。平均年龄为58岁，43%为女性。46人（49%）报告有≥1种PASC症状持续≥30天，其中13人（14%）符合PASC定义。多变量分析显示，女性（调整后的优势比[aOR]=0.32；95%置信区间[CI]，0.12 - 0.83）、移植后的年份（每增加一年aOR=0.90；95%CI，0.81 - 0.99）和替沙格韦单抗 - 西加韦单抗暴露前预防（aOR=0.33；95%CI，0.12 - 0.84）与出现≥1种PASC症状的几率显著降低相关。
PASC症状在奥密克戎时期感染的SOTR中很常见。移植后时间较长的患者和接受替沙格韦单抗 - 西加韦单抗的患者中PASC症状较少见。新的严重急性呼吸综合征冠状病毒2预防和治疗策略也应将PASC症状作为结果进行评估。
